ICU Medical, Inc. (ICUI) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. ICU Medical, Inc. develops, manufactures, and sells medical products for infusion therapy, vascular access, and vital care. The company operates as a single reportable segment. Notable recent corporate actions include the May 2025 sale of a 60% interest in its IV Solutions business to Otsuka Pharmaceutical Factory America, Inc. (OPF) and the October 2025 refinancing of its credit facilities.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $530.2 million | $604.7 million |
| Gross Profit | $206.2 million | $210.1 million |
| Gross Margin | 38.9% | 34.8% |
| Operating Income | $13.6 million | $12.9 million |
| Net Income | $30.1 million | ($15.5 million) Loss |
| Diluted EPS | $1.20 | ($0.63) |
| Cash from Operations | $38.9 million | $51.3 million |
| Cash and Equivalents (End of Period) | $288.3 million | $289.7 million |
| Total Debt (Principal) | $1.29 billion | N/A (Refinanced Oct 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 12.3% year-over-year, primarily driven by the exclusion of the IV Solutions business (sold in May 2025) which impacted the Vital Care segment. However, Consumables revenue grew 4.5% and Infusion Systems revenue grew 8.0%.
- Profitability Turnaround: The company reported a net income of $30.1 million compared to a net loss of $15.5 million in Q1 2025. This reversal was significantly aided by a discrete tax benefit of $29.2 million related to the expiration of statutes of limitations on unrecognized tax benefits.
- Margin Expansion: Gross margin improved to 38.9% from 34.8%, driven by the divestiture of the lower-margin IV Solutions business, price increases, and integration synergies, partially offset by higher tariff expenses ($13.1 million in Q1 2026 vs. $5.4 million in Q1 2025).
- Interest Expense Reduction: Net interest expense decreased to $16.5 million from $22.0 million, largely due to a $200 million debt paydown in Q2 2025 using proceeds from the IV Solutions sale.
Guidance, Outlook, and Risks
- Regulatory Contingencies: The company received a 2025 FDA Warning Letter regarding modifications to the MedFusion Model 4000 and CADD Solis VIP pumps. The company withdrew its 510(k) applications to conduct additional testing and plans to resubmit. No loss contingency has been recorded as the outcome is not yet probable or estimable. The 2021 Warning Letter was closed by the FDA in February 2026.
- Tariff Uncertainty: Following a Supreme Court ruling in February 2026 regarding the International Emergency Economic Powers Act (IEEPA), the company is evaluating potential refunds for previously paid tariffs. However, new broader tariff measures under Section 122 of the Trade Act of 1974 were immediately implemented, creating uncertainty regarding future import costs.
- Capital Expenditures: Management maintains a 2026 capital expenditure guidance range of $85 million to $100 million.
- Liquidity: The company holds $288.3 million in cash and has a $500 million revolving credit facility with no outstanding borrowings. It remains in compliance with all financial covenants.
Investor Verification Checklist
- Tax Benefit Sustainability: Verify the one-time nature of the $29.2 million tax benefit and its impact on the effective tax rate (873% for the quarter).
- FDA Resolution Timeline: Monitor the status of the resubmitted 510(k) applications for MedFusion and CADD pumps following the 2025 Warning Letter.
- Tariff Impact: Assess the net financial impact of potential IEEPA tariff refunds versus new Section 122 tariffs on the cost of goods sold.
- Debt Structure: Review the "springing maturity" provision in the credit agreement which could accelerate Term Loan A repayment if Term Loan B remains outstanding near its 2029 maturity.
- Joint Venture Performance: Track the performance of the Otsuka ICU Medical LLC joint venture, in which ICU Medical retains a 40% interest.